Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...

Graeme Sloan / Bloomberg via Getty Images The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns.

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and stand-alone flu inoculation, sending shares down sharply. The vaccine ...

Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu ...

Hardware wholesaler True Value has filed for Chapter 11 bankruptcy amid plans to sell its business to its home improvement rival Do It Best. True Value, based in Chicago, said in a Monday press ...

Japan's service-sector sentiment worsened and bankruptcy cases rose in October, data showed on Monday, casting doubt on the central bank's view the country was on track to meet its 2% inflation ...

Novavax said a participant enrolled in a mid-stage study of the combination vaccine last month reported symptoms of motor neuropathy, or damage to the nerve cells that control muscles or movement.

Novavax ends UK COVID-19 vaccine contract, agreeing to repay $123.8M in quarterly installments by 2027 as part of settlement. Vandana Singh Robinhood, Novavax, Phunware, Lucid Group, And Tesla ...

In the latest market close, Novavax (NVAX) reached $10.35, with a +1.97% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.02%.

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...